

Original Article: Asthma, Lower Airway Diseases

The importance of reducing risk in peanut allergy: Current and future therapies

Wayne G. Shreffler, MD, PhD ^{*}; Joe L. Baumert, PhD [†]; Benjamin C. Remington, PhD [‡]; Stef J. Koppelman, PhD [†]; Chitra Dinakar, MD [§]; David M. Fleischer, MD ^{||}; Edwin Kim, MD [¶]; Stephen A. Tilles, MD [#]; Jonathan M. Spergel, MD, PhD ^{**††}

^{*} Massachusetts General Hospital, Boston, Massachusetts

[†] Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, Nebraska

[‡] TNO, The Netherlands Organization, The Hague, Netherlands

[§] Stanford University, Palo Alto, California

^{||} Children's Hospital Colorado, Aurora, Colorado

[¶] University of North Carolina, Chapel Hill, North Carolina

[#] ASTHMA, Inc. Clinical Research Center; Northwest Asthma and Allergy Center, Seattle, Washington

^{**} Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

^{††} Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

ARTICLE INFO

Article history:

Received for publication September 13, 2017.

Received in revised form October 20, 2017.

Accepted for publication October 31, 2017.

Clinical Problem: Peanut Allergy

The prevalence of peanut allergy has steadily increased during the past 10 years, especially in children. A 2009 to 2010 survey of more than 40,000 children (aged 0–17 years) in the United States

found that peanut allergy was the most common food allergy, affecting 2% (1.5 million) of children nationwide.¹ Data from a 2014 meta-analysis of 29 studies from multiple European countries using various reporting methods estimated the occurrence of peanut allergy to be 0.3% (by positive food challenge result) to 4.1% (by peanut specific IgE positivity) in children aged 2 to 5 years and 0.4% (by self-reporting) to 9.8% (by peanut specific IgE positivity) in children aged 6 to 17 years.²

The burden of peanut allergy has a significant effect on the daily lives of patients, parents, and other caregivers. Allergic reactions to peanut vary and are unpredictable, ranging from skin manifestations to life-threatening systemic reactions.³ In certain regional and national data, peanut allergy has been reported to be a leading attributed cause of food allergy-related emergency department visits and cases of anaphylaxis in children⁴; it is also a common cause of fatal food allergic reactions in assembled reports of known fatalities.⁵

As a consequence of their allergies, patients, their families, and other caregivers can experience psychosocial issues and anxiety, including the fear of ingesting even trace amounts of peanut. The variability of allergic reactions and uncertainty regarding the risk of future reactions are major contributors to patient and caregiver fear.⁶ The unpredictable nature of reactions is noted in a Canadian study of 252 children 4 years or older who were diagnosed with peanut allergy and observed for 244 patient-years. During that time, the annual incidence of unintentional peanut exposure was 14.3%, and the severity of the initial reactions did not predict the severity of reactions to subsequent unintentional exposures.⁷

Reprints: Jonathan Spergel, MD, PhD, Division of Allergy and Immunology, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Wood 3325D, Philadelphia, PA 19104; E-mail: spergel@email.chop.edu.

Disclosures: All authors participated in a recent advisory board meeting sponsored by DBV Technologies during which discussion on relative risk reduction in peanut allergy brought up the need for more communication and education on this important concept. Dr Shreffler reported working as a consultant for DBV Technologies and Sanofi and receiving grant support from DBV Technologies, Aimmune Therapeutics, the National Institutes of Health, and Food Allergy Research Education (FARE). Dr Baumert reported working as a consultant for DBV Technologies. Dr Koppelman reported working as a consultant for DBV Technologies and FARE and receiving grant support from DBV Technologies, Aimmune Therapeutics, and FARE. Dr Fleischer reported working as a consultant for and receiving grant support from DBV Technologies. Dr Kim reported receiving honoraria from DBV Technologies and Aimmune Therapeutics. Dr Tilles reported working as a consultant for DBV Technologies, Aimmune Therapeutics, and FARE and receiving grant support from DBV Technologies, Aimmune Therapeutics, and FARE. Dr Spergel reported working as a consultant for DBV Technologies, FARE, and Regeneron and receiving grant support from DBV Technologies, Aimmune Therapeutics, the National Institutes of Health, and FARE. No other disclosures were reported.

Funding Sources: Editorial support was provided by IMPRINT Science, New York, New York, and funded through an unrestricted grant provided by DBV Technologies.

<https://doi.org/10.1016/j.anaai.2017.10.038>

1081-1206/© 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

The cornerstone of management for peanut allergic patients is strict elimination of peanut products from the diet. This elimination has been made somewhat easier in recent years because content labels on most packaged foods now list the most common food allergens.⁸ Although the food industry is collectively working to minimize cross-contact of peanut, packaged foods occasionally contain unintended allergen residue, prompting voluntary precautionary allergen labeling (PAL) by food manufacturers.⁹ Despite widespread use of these labels, the lack of transparency and uniformity of use because of their voluntary nature has resulted in frustration because allergic consumers may unnecessarily limit their food choice or quality of life (QoL) to avoid all packaged foods that have a PAL statement or choose to ignore some or all PAL statements and possibly increase their risk of reactions by consuming the products.⁹ Furthermore, perceived risk is heightened in food service establishments, where the opportunity for allergen cross-contact can be high, because food is prepared out of sight of customers and ingredients may be unknown, adding yet another challenge to the lives of peanut allergic patients and their parents and caregivers. Thus, patients and caregivers have limited information to assess the risk of unintentional exposure, and that risk is real.

Strategies and Evidence

Current Guideline-Based Management of Food Allergy

There is no currently approved option for the prevention or treatment of peanut allergy.^{10,11} Current standards of care are restricted to avoidance of peanut products and immediate symptom management with epinephrine to treat anaphylaxis associated with unintentional exposure.^{10,11} On the basis of collective clinical experience and published research, if treatment were available, the primary objective of most patients and caregivers would be protection from the consequences of unintentional exposure to peanuts, rather than ad lib ingestion.¹² Consequently, for most, the main goal of peanut allergy immunotherapy (in lieu of an obtainable cure) is to safely increase an individual's reactivity threshold (desensitization) to reduce the risk of allergic reactions attributable to unintentional exposure.¹³ Such therapy is preventive as opposed to an abortive treatment (eg, epinephrine) or avoidance.

The allergy field is anticipating upcoming approvals from the US Food and Drug Administration (FDA) of 2 first-time treatments for peanut allergy. There are currently 2 peanut immunotherapy strategies, epicutaneous immunotherapy and oral immunotherapy, in phase 3 development that could lead to registration in the near future.^{14,15} Sublingual immunotherapy, another mucosally targeted immunotherapeutic approach for peanut allergy, is also under investigation and has shown promise in phase 1 and early phase 2 trials.¹⁶

Relative Risk Reduction: How Much Do You Need?

Because exposure to even a small amount of peanut can elicit a reaction in some patients, desensitization that protects against a reaction to unintentional exposure to peanut could significantly increase safety for individual patients on a daily basis.¹³ With new immunotherapy options likely forthcoming, assessing the level of protection provided is important. The increase in threshold reactivity from baseline to the end of immunotherapy treatment—assuming the threshold increase is sufficient to reduce the number of reactions—is key in evaluating the effect of risk reduction for each patient. Determining the final eliciting dose (ED; the amount of allergen needed to trigger symptoms) is necessary for quantitatively measuring this effect.¹³ Whether an allergic reaction has occurred in response to a discrete threshold dose of peanut or because of the cumulative dose an individual

consumed at the time of reaction is an important consideration.¹⁷ Therefore, despite known limitations, such as cofactors, including general state of health and activity that may introduce day-to-day variability, reporting changes in a patient's sensitivity to the allergen provides additional information on how much a peanut allergic individual is able to tolerate before reacting. That is why in clinical trials the degree of treatment efficacy is evaluated by the change in ED after a double-blind, placebo-controlled food challenge.¹³

Treatment benefit is a function of pretreatment risk and risk reduction attributable to therapy (ie, absolute risk reduction). According to proceedings of the FDA Allergenic Products Advisory Committee, attaining a degree of protection that reduces the rate of reactions attributable to unintentional peanut exposure at the individual level is a clinically meaningful end point for trials evaluating peanut allergy immunotherapy.¹³ To date, the clinical utility of primary outcomes in food immunotherapy trials has been unknown. Furthermore, until recently, little was known about the risk reduction associated with a patient's increase in threshold that signifies the ability to minimize risks associated with unintentional ingestion in daily life, such as with trace amounts of peanut. The Quantitative Risk Assessment (QRA) model developed by the Food Allergy Research and Resource Program provides a probabilistic approach to assess the benefit of increasing a peanut allergic individual's threshold during immunotherapy.¹⁸ This work demonstrated the level of protection provided by immunotherapy against allergic reactions to unintentional ingestion of food products that contain trace amounts of peanut. The recently published QRA modeling approach, which matched modeled exposure to peanut protein with individual threshold levels, allowed for assessment of the potential risk reduction achieved for each peanut allergic individual.¹⁸ The QRA model compares the threshold dose of a peanut allergic individual to a diversity of exposure doses (based on an analysis of dietary data recorded in the 2003–2010 National Health and Nutrition Examination Surveys and a range of peanut protein concentrations that could be present in packaged foods) to determine the potential for a reaction on exposure to peanut protein residue. The QRA model results showed that increasing a peanut allergic individual's baseline ED threshold of peanut protein from 100 mg or less to 300 mg (equivalent to approximately 1 peanut kernel) corresponds to a 94.9% to 99.9% decrease in the risk of allergic reaction associated with unintentional exposure to trace amounts of peanut (up to 1,000 ppm) for that individual (Fig 1). Further increasing the threshold to 1,000 mg of peanut protein had an additional quantitative benefit in risk reduction for patients reacting to 300 mg or less at baseline (specifically, >98.6% risk reduction for ice cream consumption).¹⁸ The clinical relevance of increasing an allergic individual's peanut sensitivity threshold has also been characterized in a European population using the same QRA approach with European consumption data, with similar results.¹⁹ These 2 studies are based on estimated concentrations of unintended peanut protein residue detected in packaged foods (eg, cookies, ice cream, donuts, snack cakes, croissants, snack chip mixes, salty snacks) based on published retail product surveys.^{17,20–26} The products did not contain peanut as an ingredient but may have declared the potential presence of peanut residue via a voluntary PAL statement on the package label. Nonetheless, the 300-mg peanut protein threshold dose is clinically relevant, and achieving this level through immunotherapy provides a margin of safety for peanut allergic individuals who may encounter trace levels of peanut (Fig 1).¹⁸

Although achieving an individual threshold dose of 300 mg of peanut protein is predicted to provide a level of protection, standard precautions for peanut avoidance should remain in practice because patients undergoing peanut immunotherapy may still be

LOOKING AHEAD: PEANUT ALLERGY IMMUNOTHERAPY




Figure 1. Relevance of relative risk reduction in peanut allergy.¹⁸ The ability to provide a margin of safety against unintentional peanut exposure is paramount. As management of peanut allergy evolves, understanding the relative risk reduction that immunotherapy can provide is crucial. EPIT indicates epicutaneous immunotherapy. OIT, oral immunotherapy; SLIT, sublingual immunotherapy.

at risk, given that meals consumed at home, in restaurants, or at catered events could contain concentrations of peanut residue that vary from those examined in the QRA model.¹⁸ Additional QRA studies using food products other than packaged foods (eg, obtained from bakeries, restaurants, ice cream parlors, and other high-risk environments) would be useful, and some pilot studies are under way that may shed further light on the relevance of relative risk reduction in these scenarios.

Areas of Uncertainty

Shifts in Eliciting Dose Thresholds: Is There a “Magic” Dose, and How Do We Approach Other Unmet Needs?

With potential new immunotherapies on the horizon, it will be important to communicate the benefit and burden of treatment and the limitations of current evidence. Most patients and caregivers find the current practice of avoidance and treatment of reactions to be burdensome.^{6,27} However, eliminating risk in all peanut allergic patients is unrealistic until a validated curative treatment becomes available. Although patients and parents or caregivers may have a goal of reducing the frequency and severity of allergic reactions with immunotherapy, clinical trials assess reactions in controlled settings, and the correlation of clinical trial end points with the frequency and severity of reactions in the field has yet to be demonstrated. Estimates of the allergen dose unintentionally consumed in products with declared allergen are limited, and such exposures, as opposed to those attributable to cross-contamination, are likely the most clinically relevant. Markers to predict individual threshold sensitivity without the use of a food challenge are lacking, hampering our capacity to identify those who benefited from immunotherapy. In addition, there is often a hesitancy to perform food challenges in this population, reinforcing the identification of efficacy surrogates as an important unmet need. Variables that include coexisting asthma,

intercurrent infection, and physical activity at the time of allergen exposure are just some of the cofactors known to influence both ED sensitivity and reaction severity, limiting the extent to which we will be able to generalize the protective effect of immunotherapy for many patients.²⁸ The necessary reliance on the pretreatment and posttreatment ED in graded dose challenges also begs the question of whether those assessments will be needed to provide useful information for patients when and if these therapies become broadly available. Yet, despite these limitations, quality of life generally improves after immunotherapy treatment, as shown in the food-specific quality-of-life study by Factor et al.²⁹ and in a recent quality-improvement project from the Children’s Hospital of Philadelphia.³⁰

A key question we will soon confront is which patients are likely to benefit from immunotherapy: those with a low initial ED threshold or those with a high initial ED threshold. Intuitively, based on the QRA model previously discussed, there is more to gain for patients with a low initial ED, simply because their chance of reaction is greater.¹⁸ Nonetheless, peanut immunotherapy for patients with a high initial ED may still have added benefit and value.¹⁸ We do not yet have reliable means of stratifying patients and other cofactors that affect threshold sensitivity discussed above, thus imposing limits on how this can be, for the time being, implemented in clinical practice.

Guidelines

Although there are no specific guidelines for counseling patients regarding the benefits and burdens of immunotherapy, there is a need to educate them about the variety of such factors that could affect their pretreatment sensitivity to allergen consumption. Patients also need to understand the adverse event profile and other burdens of the therapy itself and the anticipated posttreatment sensitivity as well as the significant limitations we currently face in

assessing these variables. Patients and parents or caregivers would likely benefit from a more quantitative discussion explaining thresholds and risk reduction so they can better understand the potential effect of treatment on their daily lives (Fig 1).

Conclusions and Recommendations

As new therapies for peanut allergy become available, there are multiple unmet needs to address. An important first step will be to ensure that physicians, parents or caregivers, and patients have a clear understanding of the relative risk reduction anticipated from these immunotherapies so they can meaningfully weigh those against treatment burden. The recent evidence supporting the clinical relevance of a specific peanut protein threshold dose (eg, 300 or 1,000 mg) for providing a margin of safety for peanut allergic individuals is an essential concept not only for physicians but also for patients, parents, and caregivers.¹⁸ It will be important for physicians to put risk in context with treatment for patients, parents, and caregivers and to educate on the concept of relative risk reduction. Further investigation into predictors of treatment efficacy is warranted to limit the number of food challenges a patient must undergo. Appropriately setting expectations for patients, parents, and caregivers as new therapies for peanut allergy become available will be a critical aspect of overall treatment satisfaction and success.

References

- [1] Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. *Pediatrics*. 2011;128:e9–e17.
- [2] Nwaru BI, Hickstein L, Panesar SS, Roberts G, Muraro A, Sheikh A. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. *Allergy*. 2014;69:992–1007.
- [3] Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. *Pediatrics*. 1998;102:e6.
- [4] Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. *J Allergy Clin Immunol*. 2014;133:1075–1083.
- [5] Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. *J Allergy Clin Immunol*. 2001;107:191–193.
- [6] Luccioli S. Food allergy guidelines and assessing allergic reaction risks: a regulatory perspective. *Curr Opin Allergy Clin Immunol*. 2012;12:323–330.
- [7] Yu JW, Kagan R, Verreault N, et al. Accidental ingestions in children with peanut allergy. *J Allergy Clin Immunol*. 2006;118:466–472.
- [8] Lomas JM, Jarvinen KM. Managing nut-induced anaphylaxis: challenges and solutions. *J Asthma Allergy*. 2015;8:115–123.
- [9] DunnGalvin A, Chan CH, Crevel R, et al. Precautionary allergen labelling: perspectives from key stakeholder groups. *Allergy*. 2015;70:1039–1051.
- [10] Muraro A, Agache I, Clark A, et al. EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community. *Allergy*. 2014;69:1046–1057.
- [11] Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. *J Allergy Clin Immunol*. 2010;126:1105–1118.
- [12] Anagnostou K, Clark A. Author response to Marrs et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal. *Br J Dermatol*. 2015;173:1129–1130.
- [13] US Food and Drug Administration Center for Biological Evaluation and Research. Meeting of the Allergenic Products Advisory Committee. Transcript of: Allergenic Products Advisory Committee Meeting; 2016; FDA White Oak Campus, Silver Spring, Maryland.
- [14] DBV Technologies. DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children. [press release]; 2016. <https://www.dbv-technologies.com/en/investor-relations/regulated-information/3442,Global-Phase-III-Study-Viaskin-Peanut>. Accessed June 30, 2017.
- [15] Aimmune Therapeutics Inc. Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy [press release]; 2017. <http://ir.aimmune.com/news-releases/news-release-details/aimmune-therapeutics-reports-dosing-its-ongoing-phase-3-palisade>. Accessed June 30, 2017.
- [16] Burks AW, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. *J Allergy Clin Immunol*. 2015;135:1240–1248, e1241–e1243.
- [17] Zurzolo GA, Allen KJ, Taylor SL, et al. Peanut Allergen Threshold Study (PATS): validation of eliciting doses using a novel single-dose challenge protocol. *Allergy Asthma Clin Immunol*. 2013;9:35.
- [18] Baumert JL, Taylor SL, Koppelman SJ. Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy. *J Allergy Clin Immunol Pract*. doi:10.1016/j.jaip.2017.05.006. [published online ahead of print June 29, 2017].
- [19] Remington BC, Krone T, Koppelman S. P333 Quantitative risk reduction through peanut immunotherapy: safety benefits of an increased threshold in Europe. *Ann Allergy Asthma Immunol*. 2017;119:S79.
- [20] Vadas P, Perelman B. Presence of undeclared peanut protein in chocolate bars imported from Europe. *J Food Prot*. 2003;66:1932–1934.
- [21] Stephan O, Vieths S. Development of a real-time PCR and a sandwich ELISA for detection of potentially allergenic trace amounts of peanut (*Arachis hypogaea*) in processed foods. *J Agric Food Chem*. 2004;52:3754–3760.
- [22] Hefle SL, Furlong TJ, Niemann L, Lemon-Mule H, Sicherer S, Taylor SL. Consumer attitudes and risks associated with packaged foods having advisory labeling regarding the presence of peanuts. *J Allergy Clin Immunol*. 2007;120:171–176.
- [23] Pele M, Brohee M, Anklaam E, Van Hengel AJ. Peanut and hazelnut traces in cookies and chocolates: relationship between analytical results and declaration of food allergens on product labels. *Food Addit Contam*. 2007;24:1334–1344.
- [24] Remington BC, Baumert JL, Marx DB, Taylor SL. Quantitative risk assessment of foods containing peanut advisory labeling. *Food Chem Toxicol*. 2013;62:179–187.
- [25] Robertson ON, Hourihane JO, Remington BC, Baumert JL, Taylor SL. Survey of peanut levels in selected Irish food products bearing peanut allergen advisory labels. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess*. 2013;30:1467–1472.
- [26] Remington BC, Baumert JL, Blom WM, Houben GF, Taylor SL, Kruizinga AG. Unintended allergens in precautionary labelled and unlabelled products pose significant risks to UK allergic consumers. *Allergy*. 2015;70:813–819.
- [27] Salvilla SA, Dubois AE, Flokstra-de Blok BM, et al. Disease-specific health-related quality of life instruments for IgE-mediated food allergy. *Allergy*. 2014;69:834–844.
- [28] Turner PJ, Baumert JL, Beyer K, et al. Can we identify patients at risk of life-threatening allergic reactions to food? *Allergy*. 2016;71:1241–1255.
- [29] Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food-specific quality of life. *Ann Allergy Asthma Immunol*. 2012;109:348–352, e342.
- [30] Lewis M, Brown-Whitehorn T, Rooney C, Spergel J. P273 What happens when epicutaneous peanut immunotherapy ends? *Ann Allergy Asthma Immunol*. 2016;117:S103.